tiprankstipranks
BioLineRX Ltd. (IL:BLRX)
TASE:BLRX
Israel Market
BLRX
Bioline Rx
RESEARCH TOOLSreports
Want to see IL:BLRX full AI Analyst Report?

Bioline Rx (BLRX) Earnings Dates, Call Summary & Reports

3 Followers

Earnings Data

Report Date
Aug 13, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
0
Last Year’s EPS
0
Same Quarter Last Year
Analyst Consensus
―
Based on 0 Analysts Ratings

Earnings Call Summary

Q1 2026
Earnings Call Date:May 27, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call balanced meaningful scientific and clinical progress with clear commercial traction on APHEXDA and the strategic advancement of GLIX1 into first‑in‑human studies. These operational and scientific milestones are offset by weaker financial results versus the prior year — a swing from net income to net loss, a large decrease in nonoperating income, increased R&D spending and a limited cash runway into H1 2027. Management signaled optimism on pipeline progress and enrollment but provided limited disclosure on operational specifics (doses, site activations, Ayrmid commercialization details). Overall, the update reflects positive programmatic momentum but near‑term financial constraints and some executional/visibility risks.
Company Guidance
The call provided both near-term clinical timelines and detailed Q1 financials: GLIX1 has dosing underway at 3 academic centers (NYU, Northwestern, Moffitt) with the Phase I dose‑escalation expected to recruit up to 30 recurrent/high‑grade glioma patients, periodic updates planned in H2 2026 and full dose‑escalation results expected in 2027; CheMo4METPANC has a prespecified interim futility analysis when 40% of PFS events are observed (anticipated later this year); Q1 revenues were $0.5M (up $0.2M vs. $0.3M), R&D expense $2.5M (up $0.9M vs. $1.6M) driven by GLIX1, G&A $0.9M (down $0.1M vs. $1.0M), net non‑operating income $0.5M (vs. $7.6M prior year), net loss $2.6M (vs. net income $5.1M prior year), and cash and equivalents of $17.4M, which management said funds operations into the first half of 2027; commercial and preclinical metrics cited included APHEXDA sales of $2.5M in Q1 2026 (vs. $1.4M in Q1 2025) yielding $0.5M in royalty revenue to BioLineRx, GLIX1 efficacy in multiple CDx and temozolomide‑resistant PDX models, a tox safety margin (rat exposures up to 2,000 mg/kg), GBM median survival ~12–18 months, projected 2030 incidence ~18,500 U.S. and ~13,500 EU4+1 patients, and a U.S./Europe addressable market >$3.7 billion.
GLIX1 First‑In‑Human Trial Initiated and First Patient Dosed
Phase I/IIa first‑in‑human trial of GLIX1 for glioblastoma (GBM) initiated; first patient dosed at NYU Langone. Trial Phase I expected to recruit up to 30 recurrent GBM/high‑grade glioma patients to establish MTD/recommended dose based on safety, PK/PD and preliminary efficacy. Periodic updates planned in H2 2026 with full dose escalation results expected in 2027.
Compelling Preclinical GLIX1 Data Supporting BBB Penetration and Efficacy
New preclinical data show robust dose‑dependent tumor growth inhibition and survival benefit in multiple orthotopic CDx GBM models; GLIX1 demonstrated robust antitumor activity in a temozolomide‑resistant PDX where temozolomide showed no effect. GLIX1 crosses the blood‑brain barrier and restores TET2 activity, supporting development in GBM and other cancers and rationale for combinations with PARP inhibitors.
Scientific Visibility at ASCO
Two GLIX1 abstracts accepted for online publication at ASCO highlighting the preclinical dataset and mechanistic rationale, increasing scientific engagement and external validation of the program.
Motixafortide (PDAC) — Ongoing Randomized Phase IIb Trial
BioLineRx retained rights to develop motixafortide in PDAC; Columbia University is executing the randomized Phase IIb CheMo4METPANC trial in combination with cemiplimab + standard chemotherapy. Enrollment is reported to be tracking well and a prespecified interim futility analysis is planned when 40% of PFS events are observed (anticipated later in 2026).
Commercial Traction for APHEXDA
Ayrmid reported APHEXDA sales of $2.5M in Q1 2026 vs $1.4M in Q1 2025, an increase of approximately 78.6%, resulting in $0.5M of royalty revenue to BioLineRx. Management views this as meaningful early commercialization momentum.
Revenue Increase Year‑over‑Year
Reported revenues of $0.5M for Q1 2026 compared with $0.3M in Q1 2025, an increase of $0.2M (+66.7%), driven primarily by higher royalties from APHEXDA commercialization.

Bioline Rx (IL:BLRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

IL:BLRX Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 13, 2026
2026 (Q2)
0.00 / -
0―――
May 27, 2026
2026 (Q1)
-0.59 / 0.00
0―――
Mar 23, 2026
2025 (Q4)
-0.29 / 0.00
-0.879―――
Nov 24, 2025
2025 (Q3)
-0.29 / 0.00
0―――
Aug 14, 2025
2025 (Q2)
-0.29 / 0.00
0―――
May 27, 2025
2025 (Q1)
- / -
0―――
Mar 31, 2025
2024 (Q4)
-0.59 / 0.00
0―――
Nov 25, 2024
2024 (Q3)
-0.88 / 0.00
-5.86―――
Aug 15, 2024
2024 (Q2)
-1.47 / 0.00
-5.86―――
May 28, 2024
2024 (Q1)
-5.57 / 0.00
-2.93―――
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

IL:BLRX Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 27, 2026
1.401.50+7.14%
Mar 23, 2026
1.401.30-7.14%
Nov 24, 2025
1.801.800.00%
Aug 14, 2025
2.102.100.00%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioLineRX Ltd. (IL:BLRX) report earnings?
BioLineRX Ltd. (IL:BLRX) is schdueled to report earning on Aug 13, 2026, Before Open (Confirmed).
    What is BioLineRX Ltd. (IL:BLRX) earnings time?
    BioLineRX Ltd. (IL:BLRX) earnings time is at Aug 13, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of BioLineRX Ltd. stock?
          The P/E ratio of Bioline Rx is N/A.
            What is IL:BLRX EPS forecast?
            IL:BLRX EPS forecast for the fiscal quarter 2026 (Q2) is 0.